QuidelOrtho, the diagnostics company whose rapid antigen tests were the first approved for Covid-19, is exploring a sale of its testing unit as private equity firms circle healthcare targets. The company's shares have shed 90% of their value since that pandemic-era peak, compressing the valuation backdrop for any deal.
The Asset on the Block
QuidelOrtho built its profile as a Covid testing leader when its rapid antigen product won first-mover approval status during the pandemic. That franchise is now the unit under review for a potential divestiture. The source provides no deal size, no named bidders, and no timeline, so any figure attached to this process in other coverage should be treated as speculation until the company confirms.
The 90% share-price decline since the Covid testing boom defines the negotiating context: sellers who lived through the peak will face a buyer's market shaped by normalised testing volumes and a saturated diagnostics landscape.
Private Equity's Healthcare Rotation
The broader backdrop is PE capital actively scanning healthcare for entry points. Depressed public-market valuations in the diagnostics and medical-device subsectors have widened the gap between public and private pricing, a spread that buyout funds are positioned to arbitrage. QuidelOrtho's situation — a recognisable brand, a discrete sellable unit, and a stock price far from its highs — fits the profile of assets attracting that attention.
No specific private equity firms are named in the source as formal bidders or participants.
What Investors Should Watch
For buy-side holders, the operative question is whether a testing-unit sale would unlock or destroy value relative to keeping the business intact. A clean divestiture could sharpen QuidelOrtho's remaining portfolio and provide balance-sheet optionality; a distressed sale at trough multiples risks crystallising losses without a strategic rationale.
The 90% drawdown from the Covid approval moment is the number that frames every conversation about this asset. Until QuidelOrtho discloses a buyer, a price, or a formal process, the sale remains exploratory — a signal worth monitoring rather than a transaction to underwrite.